A filgrastim biosimilar has shown comparable safety and efficacy to its reference drug in phase 3 clinical trials on breast cancer patients. A new study published in the journal Annals of Oncology has shown the biosimilar filgrastim, EP2006 is similar to the reference product, Neupogen, with no clinically meaningful differences in efficacy or safety … Continue reading Study Finds Neupogen Biosimilar Safe for Breast Cancer Patients
Read moreU.K. Health Body Recommends Remicade Biosimilars Over Patented Reference Drug
Public health body NICE has favored two Remicade biosimilars ahead of the reference drug in draft guidance. The United Kingdom’s National Institute for Health and Care Excellence (NICE) has reportedly recommended two biosimilar versions of infliximab over Remicade, the top-selling original medicine patented by Janssen/MSD (Merck) – which makes more than $8 billion a year … Continue reading U.K. Health Body Recommends Remicade Biosimilars Over Patented Reference Drug
Read moreASBM Slams Australia for Backing Unsupervised Biosimilar Substitution
The Alliance for Safe Biologic Medicines calls the decision a “retrograde step” amid widespread global opposition to automatic biosimilar substitution by pharmacists. The Alliance for Safe Biologic Medicines (ASBM) has released a press release, condemning recent announcements by Australian Health Minister Sussan Ley and the Pharmaceutical Benefits Advisory Committee (PBAC) that Australia would “break … Continue reading ASBM Slams Australia for Backing Unsupervised Biosimilar Substitution
Read moreCancer Physicians Debate Biosimilars Uptake
Oncologist opinions on biosimilars and their impact on various market factors A number of the doctors interviewed by HemOnc Today disclosed affiliations with pharmaceutical companies, but their views still provide interesting insight to prevailing attitudes to biosimilars and health care. Uncertainty exists around the safety and efficacy of biosimilars, given they are similar, not … Continue reading Cancer Physicians Debate Biosimilars Uptake
Read moreHumira Biosimilars to be Most Successful
A Bloomberg survey found industry players predict Humira biosimilar copies will be most successful when launched in the EU and U.S. According to a Bloomberg Intelligence survey, biosimilar copies of AbbVie’s top-earning autoimmune anti-inflammatory drug, Humira, are expected to be the most successful biosimilars to be launched in the U.S. and Europe in the … Continue reading Humira Biosimilars to be Most Successful
Read moreEULAR Position Paper Reveals Patients Wary of Biosimilars
A paper presented at EULAR says patients don’t yet trust – or fully understand – biosimilars, and want access to clinical data. A position paper published by the European League Against Rheumatism (EULAR) reveals that patients don’t understand the science behind biosimilars and are nervous about being treated with them. In fact, “the implications … Continue reading EULAR Position Paper Reveals Patients Wary of Biosimilars
Read moreFinnish Study Finds Patients Safely Switch from Remicade to Biosimilar
A recent Finnish study has demonstrated that patients with rheumatic diseases can be safely and effectively switched from original-brand medicine to a biosimilar version. A Reuters article reports that the results of the independent study were presented at the recent European League Against Rheumatism Congress in Rome, by one of its researchers, Tuulikki Sokka … Continue reading Finnish Study Finds Patients Safely Switch from Remicade to Biosimilar
Read moreAmgen vs. Sandoz: Court Hears Oral Arguments Over Zarxio’s Patent Breach
In the latest hearing over Zarxio’s alleged patent infringements, interpretation of the wording of the BPCIA was debated. After failing twice to block Zarxio’s market entry since 2014, Amgen won an 11th-hour reprieve in May 2015, when the U.S. Court of Appeals for the Federal Circuit in Washington, granted the company an injunction – … Continue reading Amgen vs. Sandoz: Court Hears Oral Arguments Over Zarxio’s Patent Breach
Read moreSouth Korea Comes to the Fore in Biosimilars Space
Aided by government funding and big pharma partnerships, South Korea is staking its claim on biosimilars, with Celltrion and Samsung the main contenders. South Korea is pushing to be a leader in the biopharmaceuticals field, so says a recent Financial Times report. While that country’s Celltrion is already a big player in manufacturing, partnering … Continue reading South Korea Comes to the Fore in Biosimilars Space
Read moreMerck, Biogen, Samsung Partnerships Present Promising Data at EULAR Congress
At the recent EULAR Congress, the joint ventures between Merck, Biogen and Samsung bore fruit with promising biosimilars data presented. As emerging and established biopharmaceuticals companies scramble for a place in the biosimilars space, clinical trial data presented at the recent European League Against Rheumatism (EULAR) Annual Congress in Rome shows promise for more … Continue reading Merck, Biogen, Samsung Partnerships Present Promising Data at EULAR Congress
Read more